A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910